SPOK USA Mobility: Price-to-Projected Revenue Ratio

spok.com - graphic logo of issuer SPOK

Spok Holdings, Inc. (SPOK) maintains a monopoly in the emergency sector due to its ownership of unique radio frequencies. However, the obsolescence of paging systems and the slow transition of clinics to software create certain risks. The company remains a key partner for hospitals, integrating communications into medical systems. The forward P/S of Spok Holdings, Inc. (SPOK) on GURU.Markets reflects valuation dynamics, where 1.80 determines the latest business resilience valuation metric.

spok.com - SPOK Market Cap to Projected Revenue (period 07/04/2022 - 11/17/2026)

Spok Holdings, Inc. - analytical breakdowns and key metrics (SPOK)

- market price and analyst price targets:
Basic company analysis:SPOK (USA Mobility)
Original product of USA Mobility

Forward P/S determines the market value of an asset relative to expected sales volume, allowing for an assessment of whether a business is overvalued or undervalued based on projected revenue streams. By analyzing the forward price-to-sales valuation trend, an investor can compare the capitalization rates of Spok Holdings, Inc. (SPOK) with the sustainable margins derived from its monopoly over critical communications in US hospitals, thereby identifying the gap between market expectations and actual software scaling.

Analysis of competing companies

Price-to-Projected Revenue Ratio Veeva Corp VEEV|Price to Expected Revenue Ratio DOCS (Doximity, Inc.)|HQY: Forward Price-to-Revenue Multiple|Forward Price to Sales WAY (waystar.com)|CorVel Corp. (CRVL) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Privia Health (PRVA)|Price-to-Projected Revenue Ratio Huron Corp|Market Cap to Projected Revenue CERT (Certara Corp)|Price-to-Projected Revenue Ratio Omnicell (OMCL)|GoodRx Holdings, Inc. - Market Cap to Projected Revenue|Schrödinger - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Phreesia Inc (PHR)|OMDA: Forward Price-to-Revenue Multiple|Forward Price to Sales EVH (Evolent Health, Inc.)|HSTM: Forward P/S Multiple|DH: Price to Expected Revenue Ratio|CCSI (Consensus) - Forward P/S Multiple|Price-to-Projected Revenue Ratio AGL|Forward P/S Multiple ABSI|Market Cap to Expected Sales Ratio So-Young Corp|Price-to-Projected Revenue Ratio National Research NRC|Forward Price to Sales OPRX|trubridge.com - Forward P/S Multiple|SLP (Simulations Plus) - Market Cap to Projected Revenue|SOPHiA GENETICS SA (SOPH) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Health Catalyst, Inc.|Forward Price-to-Revenue Multiple CCLD|researchsolutions.com (RSSS) - Market Cap to Expected Sales Ratio|Forward P/S Multiple DLHC|OneMedNet Corp - Market Cap to Projected Revenue|Forward P/S Multiple SCNX (Scienture Corp)|Price to Expected Revenue Ratio HCTI (Healthcare Triangle Corp)|iSpecimen Corp - Forward P/S Multiple|Forward Price to Sales BFRG (bullfrogai.com)|WORX: Forward P/S Multiple|Forward Price-to-Revenue Multiple MSP Recovery|Price-to-Projected Revenue Ratio icoreconnect.com|MEDS: Forward Price to Sales|Price-to-Projected Revenue Ratio Orgenesis Inc. (ORGS)|Market Cap to Expected Sales Ratio R1 RCM, Inc.|Forward P/S Multiple SHCR (sharecare.com)|Market Cap to Expected Sales Ratio Streamline Health Solutions, Inc. (STRM)|SYRA - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Apollo Medical Holdings Inc. AMEH|Model N (MODN) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue NXGN